World Journal of Meta-Analysis - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Homepage

Online Submission

Number of total visits: 517311

Number of visits today: 229

Number of downloads: 203179

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Curtis JR, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N, Nduaka CI, Koram N, Cappelleri JC, Chan G, Modesto I, Lichtenstein GR. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. Inflamm Bowel Dis 2021;27:1394-408. [PMID: 33324993 DOI: 10.1093/ibd/izaa289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]

For:

Curtis JR, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N, Nduaka CI, Koram N, Cappelleri JC, Chan G, Modesto I, Lichtenstein GR. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. Inflamm Bowel Dis 2021;27:1394-408. [PMID: 33324993 DOI: 10.1093/ibd/izaa289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]

Number	Citing Articles
1	Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 2021. [PMID: 34854095 DOI: 10.1111/apt.16712] [Reference Citation Analysis]
2	Abraham B, Glassner K. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. Curr Opin Gastroenterol 2021;37:344-50. [PMID: 33731642 DOI: 10.1097/MOG.0000000000000738] [Reference Citation Analysis]
3	Wang L, Hu Y, Song B, Xiong Y, Wang J, Chen D. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease. Inflamm Res 2021;70:753-64. [PMID: 34212215 DOI: 10.1007/s00011-021-01482-x] [Reference Citation Analysis]
4	Sands BE, Long MD, Reinisch W, Panés J, Loftus EV, Nduaka CI, Soonasra A, Mundayat R, Lawendy N, Chan G, Friedman GS, Su C. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis 2021:izab056. [PMID: 33742652 DOI: 10.1093/ibd/izab056] [Reference Citation Analysis]
5	Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M. Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals (Basel) 2021;14:637. [PMID: 34209234 DOI: 10.3390/ph14070637] [Reference Citation Analysis]